List of Excipients in Branded Drug SUBOXONE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
INDIVIOR INC	SUBOXONE	buprenorphine hydrochloride, naloxone hydrochloride	12496-1202	ACESULFAME POTASSIUM
INDIVIOR INC	SUBOXONE	buprenorphine hydrochloride, naloxone hydrochloride	12496-1202	CITRIC ACID MONOHYDRATE
INDIVIOR INC	SUBOXONE	buprenorphine hydrochloride, naloxone hydrochloride	12496-1202	FD&C YELLOW NO. 6
INDIVIOR INC	SUBOXONE	buprenorphine hydrochloride, naloxone hydrochloride	12496-1202	HYPROMELLOSES
INDIVIOR INC	SUBOXONE	buprenorphine hydrochloride, naloxone hydrochloride	12496-1202	MALTITOL
INDIVIOR INC	SUBOXONE	buprenorphine hydrochloride, naloxone hydrochloride	12496-1202	POLYETHYLENE GLYCOL
INDIVIOR INC	SUBOXONE	buprenorphine hydrochloride, naloxone hydrochloride	12496-1202	SODIUM CITRATE

Suboxone Excipient Strategy and Commercial Opportunities in Buprenorphine-Naloxone Products

Last updated: August 9, 2026

Suboxone is an established buprenorphine/naloxone product with limited remaining opportunity in the core molecule and substantial opportunity in excipient-enabled differentiation. The most attractive strategies are improved sublingual film performance, faster dissolution, taste masking, moisture control, child-resistant unit dosing, abuse-deterrent packaging, and lower-cost manufacturing. Patent protection around the original product has largely expired or been weakened by litigation, so commercial value now depends on formulation execution, regulatory positioning, manufacturing scale, and payer access.

What is Suboxone and which excipients are used?

Suboxone contains buprenorphine hydrochloride and naloxone hydrochloride dihydrate. The product is approved for medication-assisted treatment of opioid use disorder and is marketed primarily as a sublingual film in multiple strengths.

The FDA-approved film uses a polymeric matrix that dissolves in the oral cavity and delivers the active ingredients across the sublingual mucosa. Public labeling identifies the following inactive ingredients:

Excipient or material	Functional role
Polyethylene oxide	Film-forming polymer and matrix former
Polyvinyl alcohol	Film strength and flexibility
Maltitol	Film plasticizer, sweetener and bulking agent
Citric acid	pH adjustment and taste modulation
Sodium citrate	Buffering capacity
FD&C Yellow No. 6	Colorant
Flavoring components	Organoleptic masking

The exact commercial performance of the film depends on polymer molecular weight, polymer ratios, solvent system, drying conditions, film thickness, residual moisture, cutting accuracy and packaging barrier properties. These variables can matter as much as the nominal excipient list.

The Suboxone sublingual tablet historically used a different excipient system, including lactose monohydrate, mannitol, corn starch, povidone, citric acid, sodium citrate, magnesium stearate, acesulfame potassium and flavoring materials. The tablet and film should be treated as separate formulation platforms for regulatory, manufacturing and patent analysis. [1]

What excipient strategy does Suboxone use?

Suboxone’s excipient strategy addresses four product requirements: rapid oral dissolution, adequate mucosal residence, acceptable taste and controlled delivery of buprenorphine with naloxone.

Sublingual film architecture

The film must be thin enough to dissolve within a clinically acceptable period but strong enough to withstand converting, packaging, transport and handling. Polyethylene oxide and polyvinyl alcohol provide the structural basis for the dosage form. Maltitol contributes flexibility and improves palatability.

A commercial film formulation must balance:

• Dissolution speed
• Wetting and hydration
• Mucoadhesion
• Film tensile strength
• Folding and cracking resistance
• Content uniformity
• Residual solvent levels
• Moisture uptake
• Taste and mouthfeel
• Stability during storage

Increasing polymer content can improve mechanical strength but may slow dissolution. Increasing plasticizer or polyol content can improve flexibility and taste while increasing moisture sensitivity. Buffer levels influence pH, drug solubility and the sensory profile.

Taste management

Buprenorphine and naloxone products can produce bitterness, numbing and unpleasant aftertaste. Taste masking is commercially important because adherence depends on repeated daily use.

Potential approaches include:

• Polyol-based sweetness
• Flavor systems compatible with sublingual delivery
• Ion-exchange resins
• Cyclodextrin complexes
• Lipid or polymeric microencapsulation
• Reduced exposure of uncomplexed drug at the tongue surface
• pH control to reduce bitterness and irritation

Taste masking must not impair rapid release or reduce transmucosal absorption. A formulation that improves palatability but creates delayed or variable buprenorphine exposure may face bioequivalence and clinical acceptance problems.

Moisture and packaging control

Film dosage forms are highly sensitive to water activity. Moisture can alter flexibility, dissolution, polymer hydration and active-ingredient stability. High-barrier foil packaging is therefore part of the product strategy, not a secondary packaging decision.

Commercially relevant packaging options include:

• Individually sealed foil pouches
• Child-resistant cartons
• Unit-dose blister systems
• Tamper-evident packaging
• High-barrier multilayer laminates
• Desiccant-enabled secondary packaging

Packaging changes can create regulatory and intellectual-property opportunities when they alter shelf life, abuse resistance, dose integrity or patient handling.

What patents protect Suboxone formulations?

Suboxone’s original formulation protection centered on the buprenorphine/naloxone combination, sublingual delivery and film dosage-form technology. Key U.S. patent families associated with Suboxone film included patents held by Indivior and related entities.

Patent or patent family	Relevance	Commercial status
U.S. Patent No. 8,603,514	Sublingual film dosage form and composition	Subject to invalidity litigation and no longer a reliable barrier to ordinary generic entry
U.S. Patent No. 8,900,497	Buprenorphine/naloxone film technology	Challenged in ANDA litigation
U.S. Patent No. 9,421,195	Later film and dosage-form claims	Challenged and litigated in connection with generic entry
Related international families	Film composition, manufacturing and delivery claims	Coverage varies by country and expiration date

Indivior’s principal Suboxone film patents were challenged by generic manufacturers, including Dr. Reddy’s Laboratories and Teva. U.S. courts rejected or limited important patent claims, reducing the ability of the estate to block generic film competition. The Federal Circuit and district court decisions in the Suboxone litigation materially changed the commercial value of the asserted patents. [2][3]

Patent analysis should separate three categories:

1. Core product patents covering the buprenorphine/naloxone film.
2. Manufacturing patents covering casting, drying, converting and packaging.
3. Follow-on patents covering abuse deterrence, dosing, polymer systems and administration methods.

The third category can remain commercially relevant even after core composition patents expire, but claim scope and validity risk are generally narrower.

When did Suboxone lose exclusivity?

Suboxone’s FDA new-drug exclusivity expired years before the current generic market developed. The principal commercial barrier was patent-based, not current FDA exclusivity.

Exclusivity category	Suboxone position
New chemical entity exclusivity	Expired
Five-year NCE exclusivity	Not applicable to the current commercial period
Three-year clinical investigation exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Film patent exclusivity	Principal barrier, substantially reduced by litigation
Generic entry	Established in the U.S.

FDA approved generic versions of buprenorphine/naloxone sublingual tablets and films through the ANDA pathway. Generic manufacturers have competed on price, supply reliability, payer contracts and dosage-form availability rather than on new active ingredients. [4]

What is the Orange Book status of Suboxone?

Suboxone film and tablet products have been associated with Orange Book-listed patents. Orange Book listings identify patents submitted by the NDA holder and do not independently establish patent validity or enforceability.

For commercial analysis, Orange Book review should distinguish:

• Listed patents that have expired
• Listed patents removed after litigation
• Patents subject to Paragraph IV certifications
• Patents not blocking approval because of expiration or statutory timing
• Patents covering only a specific dosage form or method of use

Orange Book-listed patents are most relevant to ANDA timing when a generic applicant files a Paragraph IV certification. The filing can trigger patent litigation and a potential 30-month stay of FDA approval under the Hatch-Waxman framework. [5]

Which companies challenged Suboxone patents?

The most significant challenges came from generic manufacturers seeking approval for buprenorphine/naloxone sublingual film.

Dr. Reddy’s Laboratories

Dr. Reddy’s challenged Indivior’s Suboxone film patents and obtained approval for a generic film product. Litigation addressed written-description support, claim scope and whether Indivior could preserve market exclusivity through later-issued patents.

Teva Pharmaceuticals

Teva also pursued generic buprenorphine/naloxone film approval and challenged patents associated with the branded product. Teva’s participation increased competitive pressure and reduced the practical value of the branded film patent estate.

Other generic manufacturers

Additional ANDA applicants have competed in sublingual tablet and film products. The number of approved or commercially active suppliers can change as manufacturing, supply and litigation conditions evolve. The market has historically included manufacturers such as Sandoz, Mylan/Viatris, Alvogen, Teva and Dr. Reddy’s.

What formulations are protected by Suboxone-related patents?

The most commercially relevant formulation claims have involved:

• Buprenorphine and naloxone in a single sublingual film
• Polymer matrices that control dissolution
• Mucoadhesive oral films
• Specific ratios of active ingredients
• Film thickness and dose uniformity
• Polymer molecular-weight ranges
• Drying and solvent-removal processes
• Packaging systems that protect moisture-sensitive films
• Abuse-deterrent or misuse-resistant delivery systems

Follow-on developers should avoid treating the excipient list as the full invention. Patentable differentiation may arise from the interaction between excipient levels, manufacturing parameters and performance outcomes.

Potential claimable attributes include:

• A defined dissolution profile
• Lower residual moisture
• Improved tensile strength
• Reduced brittleness
• Improved content uniformity at low dose
• Reduced bitter taste
• Stable performance under accelerated conditions
• Reduced dose dumping when exposed to water or alcohol
• Manufacturing methods that reduce waste and improve roll-to-roll yield

How strong is the Suboxone patent estate?

The original estate is materially weaker than it was before generic entry. Core film patents faced successful validity and infringement challenges, and generic manufacturers have obtained FDA approval.

The remaining value is concentrated in narrower technology and implementation areas:

Estate component	Relative strength
Buprenorphine/naloxone combination	Low as a blocking strategy
Basic sublingual film concept	Low to moderate
Specific polymer and excipient ratios	Moderate, depending on claim construction
Manufacturing process	Moderate if process evidence is difficult to design around
Packaging and moisture control	Moderate
Abuse-deterrent improvements	Potentially meaningful
New clinical method of use	Limited unless supported by new clinical data

A follow-on formulation patent is strongest when it claims a measurable product property linked to a defined composition and supported by comparative data. Broad claims based only on substituting one common excipient for another are more vulnerable to obviousness challenges.

What excipient commercial opportunities exist for Suboxone competitors?

1. Improved sublingual films

A supplier or drug developer can pursue films with:

• Faster dissolution
• Lower mouth residue
• Better taste
• Greater flexibility
• Improved dose uniformity
• Lower manufacturing scrap
• Longer shelf life

The commercial opportunity is strongest where the improvement is visible to patients or reduces manufacturing cost.

2. Alternative polymer systems

Potential polymer platforms include hydroxypropyl methylcellulose, hydroxypropyl cellulose, pullulan, povidone, polyethylene oxide and polyvinyl alcohol combinations. Each changes film strength, hydration, mouthfeel and drying behavior.

A substitute polymer must satisfy FDA inactive-ingredient precedent and support a complete chemistry, manufacturing and controls package. Novel use levels may require additional justification even when the excipient itself is well established.

3. Taste-masking systems

Taste-masking technologies can support premium generic positioning, adherence claims and lifecycle-management products. Resin complexes and encapsulated drug particles may reduce bitterness, but they introduce additional controls for particle size, release, content uniformity and mucosal absorption.

4. Abuse-deterrent formulations

Buprenorphine products face misuse risks because the active ingredient is an opioid. Excipient systems that resist crushing, extraction, injection or rapid release may support a differentiated product. Commercial success would depend on validated abuse-deterrence data, physician acceptance and payer recognition.

Abuse-deterrent claims must be technically credible. A formulation that becomes injectable after simple aqueous extraction is unlikely to support a strong commercial or regulatory position.

5. Pediatric and caregiver-friendly packaging

The FDA labeling for Suboxone includes important handling and accidental-exposure warnings. Child-resistant unit-dose packaging, clear dose identification and tamper evidence can reduce medication errors and support institutional use.

Packaging improvements may also create licensing opportunities for film converters, foil suppliers and contract manufacturers.

6. Manufacturing and contract development

The manufacturing process offers opportunities for contract development and manufacturing organizations with expertise in:

• Continuous film casting
• Solvent drying
• Roll-to-roll converting
• Low-dose content uniformity
• High-barrier pouching
• Automated inspection
• Moisture-controlled packaging
• Scale-up from laboratory casting to commercial web production

Manufacturing IP can be commercially valuable because a generic applicant may design around composition claims but still need an efficient and reproducible production process.

How does Suboxone compare with competing buprenorphine products?

Product	Active ingredient	Dosage form	Commercial position
Suboxone	Buprenorphine/naloxone	Sublingual film and tablet	Branded reference product with generic competition
Subutex	Buprenorphine	Sublingual tablet	Earlier buprenorphine-only platform; more limited current role
Zubsolv	Buprenorphine/naloxone	Sublingual tablet	Differentiated tablet with taste and dosing claims
Bunavail	Buprenorphine/naloxone	Buccal film	Film-based alternative; commercial availability has been limited
Sublocade	Buprenorphine	Extended-release injection	Long-acting product with different administration and patent profile
Brixadi	Buprenorphine	Extended-release injection	Long-acting competitor with monthly and weekly dosing

Suboxone competes most directly with generic sublingual films and tablets. Sublocade and Brixadi compete for the broader opioid-use-disorder treatment market but use different delivery technologies and do not depend on the same excipient architecture. [6][7]

What generic entry risks exist for Suboxone?

Generic entry risk is high for the basic product because:

• FDA exclusivity has expired.
• Generic tablets and films are approved.
• Core patent barriers have been weakened.
• Multiple manufacturers can compete.
• Prescribers are familiar with the active-ingredient combination.
• Payers generally favor lower-cost products.

Remaining risks for generic developers include:

• FDA bioequivalence requirements
• Film content-uniformity failures
• Dissolution differences
• Taste and adherence problems
• Manufacturing yield losses
• Moisture-related stability failures
• Supply interruptions
• Patent litigation over follow-on claims
• State-level substitution and formulary rules

The most credible launch strategy is a reliable, low-cost product with equivalent dosing, acceptable taste and robust supply rather than a marginal excipient change unsupported by clinical or commercial evidence.

What licensing deals and partnership opportunities exist?

Commercial opportunities are more likely to involve technology licensing than rights to the original Suboxone brand. Attractive assets include:

• Sublingual film platforms
• Taste-masking systems
• Abuse-deterrent excipients
• High-barrier packaging
• Continuous manufacturing processes
• Drug-device or unit-dose packaging systems
• Long-acting buprenorphine delivery technologies

Potential counterparties include generic pharmaceutical companies, specialty opioid-use-disorder companies, excipient manufacturers, film technology developers and contract manufacturing organizations.

A licensing package is stronger when it includes freedom-to-operate analysis, reproducible manufacturing data, comparative dissolution results, stability data and a defined FDA regulatory pathway.

Key Takeaways

• Suboxone’s core exclusivity has ended, and generic competition is established.
• The main commercial opportunity is excipient-enabled differentiation, not recovery of broad molecule-level exclusivity.
• Polyethylene oxide, polyvinyl alcohol, maltitol, citrate buffers and flavor systems define important performance characteristics of the reference film.
• Taste, dissolution, flexibility, moisture stability and packaging are the primary formulation targets.
• Manufacturing-process and packaging patents may retain value after core film patents expire.
• Generic entry risk is high, but technically difficult film manufacturing creates barriers to reliable supply.
• The strongest licensing opportunities involve film platforms, taste masking, abuse deterrence and high-barrier packaging.
• Suboxone competes with generic sublingual products and with long-acting buprenorphine injections such as Sublocade and Brixadi.

FAQs

Can a new excipient create patent protection for a Suboxone generic?

Yes, but the excipient substitution must produce a non-obvious formulation or measurable performance improvement. A routine replacement of one conventional film former with another is vulnerable to obviousness challenges.

Is a buprenorphine/naloxone oral film eligible for a 505(b)(2) application?

A 505(b)(2) pathway may be relevant when the product differs materially from the reference product and relies partly on FDA findings for an approved drug. A straightforward equivalent generic film generally fits the ANDA pathway instead.

Which excipients are most important for Suboxone film stability?

The polymer system, polyol content, citrate buffer, residual moisture and packaging barrier are central. Moisture control can affect mechanical strength, dissolution, stability and dose uniformity.

Can a taste-masked Suboxone product obtain three years of FDA exclusivity?

New clinical investigations essential to approval of a product change may support three-year exclusivity in limited circumstances. A purely pharmaceutical reformulation without qualifying clinical data may not receive that protection.

Do biosimilar rules apply to Suboxone?

No. Suboxone contains chemically synthesized small-molecule active ingredients. Generic drug rules under the ANDA framework, not the biosimilar pathway, govern equivalent buprenorphine/naloxone products.

References

1. U.S. Food and Drug Administration. (2023). Suboxone (buprenorphine and naloxone) sublingual film prescribing information.
2. U.S. Court of Appeals for the Federal Circuit. (2020). Indivior Inc. v. Dr. Reddy's Laboratories, S.A., patent litigation decisions concerning Suboxone film.
3. U.S. District Court for the District of Delaware. (2019). Indivior Inc. v. Dr. Reddy's Laboratories, S.A., decisions concerning U.S. Patent Nos. 8,603,514 and 8,900,497.
4. U.S. Food and Drug Administration. (2024). Drugs@FDA: Suboxone and approved abbreviated new drug applications.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
6. U.S. Food and Drug Administration. (2023). Sublocade (buprenorphine extended-release) injection prescribing information.
7. U.S. Food and Drug Administration. (2023). Brixadi (buprenorphine extended-release) injection prescribing information.